Arterial Vascular Engineering AVEI Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Scott Overholser who wrote (375)	10/25/1998 12:51:00 AM
From: mmeggs	Read Replies (2) of 410

This is a company that has CRUSHED expectations for the last three quarters. Each quarter analysts bump their estimates but issue a warning that "competitive pressures" may become evidenced. Yet for the last year, they're have not. But because this "warning" is out there, it is never able to sustain any momentum. This quarter was highlighted by the fears of: The Bard aquisition may not go smoothly. They may lose mroe market share when BSX introduces the Nir stent - AGAIN. (Had to be pulled becuase it popped the ballons!) Guidant may get approval for the Duet II in the next quarter. Old fears like decreasing margins, prices coming down due to competition, one trick pony, etc. Clinical data has shown the gfx to be the best stent out there, with the possible exception of the yet-to-be-introduced Duet II. Of course the gfx II comes out 1Q '99, and it should do at least as well, if history is any indication. I don't know. Frustrating. You could pose quesitons like this about any company. But to say that they didn't exceed expectations by as high a percentage as two previous quarters, and that is why they are down, is patently absurd.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next